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ABSTRACT 
Zachary T. Francis 
ANALYSIS OF THE CRYPTIC PROMOTER IN THE 5’-UTR OF P27 
Cyclin Dependent Kinase regulation is often manipulated by cancer cells to promote 
unlimited proliferation.  P27 is an important regulator of Cyclin E/CDK 2, which has 
been found in low amounts in many types of malignant cancers.  Lovastatin has been 
shown to cause cell cycle arrest in the G1 phase of the cell cycle by increasing the P27 
protein.  There has been some question, however, if lovastatin regulates P27 at the 
transcriptional or translational level.  Although it has been claimed that P27 expression 
regulation is due to an IRES located in its 5’UTR, other studies suggested that P27 
expression is regulated at the level of transcription.  To further investigate the regulation 
mechanism of P27 expression, the 5’-UTR of P27 and its deletion mutants were 
examined using a luciferase reporter gene in HeLa cells following exposure to lovastatin.  
It was found that lovastatin stimulated a significant 1.4 fold increase in its promoter 
activity of the full length 5’UTR (575). Deletion of 35 nucleotides from the 5’ end of the 
UTR eliminated the lovastatin-induced increase in promoter activity.  Further mapping 
analyses of the first 35 bases showed that two regions, M1 (575-559) and M3 (543-527), 
were less sensitive to lovastatin than the other mutated constructs.   
Since M1 and M3 still showed some activity, a construct was created with deletions 
in both the M1 and M3 regions.  This showed no increase in luciferase activity when 
exposed to lovastatin.  Looking at RNA levels, there was a 1.5 fold increase in RNA 
when the full length 5’UTR was inserted into HeLa cells and exposed to 81 µM of 
lovastatin.  In contrast, there was no increase in RNA when M1/M3 (575-559; 543-527) 
 v 
was inserted into HeLa cells and exposed to 81 µM of lovastatin.  In addition, there was a 
1.6 fold increase in endogenous P27 RNA levels after HeLa cells were exposed to 81 µM 
of lovastatin.  In all of these experiments, there seems to be two promoters that work 
cooperatively:  M1 (575-559) and M3 (543-527).   
Jian-Ting Zhang, Ph.D., Chairman 
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CHAPTER 1.  INTRODUCTION 
1.1  Overview of Cancer:  Initiation, Promotion, Progression 
As shown in Figure 1, cancer can be divided into three stages:  initiation, promotion, 
and progression.  Initiation is the stage where an “initiated cell” or newly transformed 
cell is created.  This irreversible process begins when chemical carcinogens interact with 
DNA to form stable adducts or mutations (such as transitions, transversions, or small 
deletions) which remain unless removed by repair.  Cell division of transformed cells is 
required to “fix” cells in their mutated state.  In addition, there is no threshold for 
initiators.  It is conceivable that one dose of an initiating carcinogen is enough to form a 
tumor (Gamper, 1980). 
 
 
 
 
 
 
 
 
 
Figure 1:  The stages of carcinogenesis.  When an initiating carcinogen is added, there is a 
permanent genetic change that occurs if the DNA is not repaired.  With the help of 
promoting agents, the initiated cell can then be replicated to form a preneoplastic lesion.  
Finally, progression involves multiple mutations in various genes and karyotypic instability.  
In the progression stage, we will observe benign and malignant tumors that are formed.  
(Adapted from www.unc.edu chemical carcinogenesis PowerPoint, 2007)  
Figure 1 
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Promotion is a reversible stage that involves a reagent increasing the growth of an 
initiated cell.  Instead of creating new types of cancer cells, promoters have a tendency to 
increase the growth of tumors through cellular proliferation and/or inhibition of 
apoptosis.  Progression is the uncontrolled growth of a tumor.  This stage is characterized 
by genetic changes which lead to different levels of activity for structural proteins, 
growth factors, and proteases (Hennings, 1993).   
1.2  Cell Cycle in Relationship to Tumor Initiation, Promotion, and Progression 
 
The cell cycle is divided into four distinct phases:  G1-First gap phase to prepare cells 
for DNA synthesis, S-for DNA synthesis, G2-second gap phase and M-for cell division 
(See Figure 2).  In addition to these four phases, cells can also be in a quiescent state or 
G0 phase (Caldon, 2006).  In the G0 phase, cells are not dividing.  If cells choose to 
undergo cell division, they will leave G0 and enter the G1 phase of the cell cycle.  
Understanding how cells pause the cell cycle is essential to understanding the 
mechanism behind cellular proliferation.  Stopping cell division allows for DNA repair 
after genetic integrity has been compromised by DNA damaging agents.  Surveillance 
control mechanisms ensure proper completion of early events and cellular integrity 
before subsequent steps can occur (Shackelford, 1999).  If damage is too severe to be 
adequately repaired, the cell may then undergo apoptosis.   
Cyclin Dependent Kinases (CDKs) help to promote cell cycle progression.  Mitogens 
and growth factors promote early events that commit cells to division.  These events 
include the induction of D and E-type cyclins as well as phosphorlyation of the 
retinoblastoma protein (pRB).  The point at which the withdrawal of growth factors no 
longer halts cell cycle progression is called the G1 restriction point (Shackelford, 1990).  
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Kinases can be regulated at many levels to halt cell cycle progression and allow for DNA 
repair.  Antiproliferative signals from proteins such as P27 and P16 help to prevent the 
formation of CDK complexes (Shackelford, 1990).  When these mechanisms of CDK 
inhibition are blocked by carcinogens, transformed cells can then proliferate without 
DNA repair.  Thus, understanding CDKs and their mechanism regulation is important for 
designing approaches to prevent the formation and spread of cancer cells.  
 
 
Figure 2:  Diagram of Cyclin Dependent Kinases and where they act in the cell 
cycle.  Helps to show how Cyclin Dependent Kinases are essential in cell cycle 
progression.  (Adapted from a figure by Shakelford, 1999) 
 
Figure 2 
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1.3  Cyclin Dependent Kinases 
CDKs are dimeric complexes comprised of both a catalytic and a regulatory subunit.  
These seriene/threonine kinases can be divided into two groups.  Members of the first 
group include cyclin A dependent kinases 1 and 2 and cyclin B dependent kinase 1.  
These CDKs help to promote G2-M phase transition.  The other group of CDKs include 
cyclin D dependent kinases 4 and 6 as well as cyclin E dependent kinase 2.  These 
cyclins, D and E, facilitate G1-S transition (Shapiro 2006; Sherr 1999). 
Cyclins are required for the activation of CDKs.  When cells are stimulated by growth 
factors or mitogenic signals, they leave the G0 phase to enter the cell cycle.  The first 
cyclins to be synthesized during this period are the D type cyclins.  These cyclins 
associate with CDK4 or CDK6 and function early in the G1 phase.  Cyclin E associates 
with CDK2 from the mid to late G1 phase of the cell cycle (Lee, 2003; Sherr 1999).  The 
Cyclin D1/CDK4 complex helps to mediate the phosphorlyation of retinoblastoma 
protein (RB).  In a hypophosphorylated state, Rb interacts with E2F transcription family 
members.  This family targets genes that are involved in G1-S transition.  By interacting 
with E2F, Rb prevents the transcription of genes that are required for S phase entry.  In 
addition, Rb can also recruit histone deaceytlases to the promoters of genes that are 
required for entering this phase of the cell cycle.  These deacetylases help to lower 
transcription by removing acetyl groups from lysines on histone proteins.  When Rb is 
phosphorylated, however, it no longer interacts with E2F and the transcription of genes 
that are required for entering the S phase occur uninterrupted (Shapiro, 2006; Sherr 
1999). 
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1.4  CDK Regulation 
CDKs have a number of positive regulators.  C-Myc has been known to upregulate 
the transcription of CDK4 and cyclin D2 (Bouchard, 1999; Hermeking, 2000).  Another 
positive regulator of CDK4 is p34 SEI 1 which activates its kinase activity at lower 
concentrations (Li, 2004).  In addition, breast cancer cells have also been known to 
express a low molecular weight form of cyclin E which can increase the G1 to S phase 
transition when bound to CDK 2 (Lee, 2003).   
CDKs also have a number of negative regulators.  One of the main classes of these 
regulators are called CDK inhibitors or CDKIs.  There are two main classes of CDKIs.  
The INK 4 family (p15, p16, p18) bind to and distort the catalytic cyclin binding site 
(Copfert, 2003).  The Cip/Kip family (P21, P27, and P57) all share a highly conserved 
amino terminal domain that mediates cyclin and CDK binding (Zhang, 1997; Gopfert, 
2003).  Although the Cip/Kip family has a sequence that is highly conserved, much of 
their sequence is different which suggests that the proteins have distinct function and 
regulation (Benson, 2008).  For example, P21 causes cell cycle arrest in the G1 and G2 
phases in response to DNA damage whereas P57 regulates the cell cycle during 
embryonic development.  However, P27 is upregulated in quiescent cells and is rapidly 
downregulated in other phases of the cell cycle (Benson, 2008).  The protein P27 is being 
explored further because of its ability to induce cell cycle arrest by inhibiting CDK2 in 
the G1 phase of the cell cycle.   
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1.5  P27:  A Cip/Kip Inhibitor of CDK 2 
P27 is a 27 kilodalton protein with its gene located on chromosome 12 (Lloyd, 1999).  
The protein is a prognostic indicator in many forms of cancer.  Low levels of P27 protein 
in breast, prostate, and ovary cancers have all been shown to correlate with a poor 
medical prognosis (Benson, 2008).  Transgenic mice with a P27 null (-/-) genotype have 
been known to display multiorgan hyperplasia.  In addition, both P27 nullzygous (-/-) and 
heterozygous mice (-/+) were predispositioned to tumorigenesis when exposed to gamma 
radiation (Paris, 2006; Gophert, 2003).  In a study published in 2006, Troncone et al. 
analyzed P27 expression in 10 benign and 40 malignant breast lesions using 
Figure 3: Schematic of how Cyclin Dependent Kinases are regulated.  Regulation of Cyclin 
Dependent Kinases can occur at many levels.  Antiproliferative signals help to prevent the 
induction of cyclin D; proteins such as P16, P21, and P27 help to inhibit complex formation 
and/or activation.  Cancer cells try to manipulate this process by inhibiting one or more of 
these CDKIs  (Shakelford, 1999). 
Figure 3 
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immunostaining and showed that P27 protein was significantly lower in carcinomas than 
in benign lesions (Troncone, 2004).   
P27 has also been shown to induce cell cycle arrest in the G1 phase of the cell cycle.  
In 1997, Millard found that the expression of P27 in the G1 phase is much higher than in 
any other phases of the cell cycle (Millard, 1997). This observation suggests that high 
P27 expression results in G1 phase cell cycle arrest.  Indeed, Rao et al. showed that 
lovastatin induces G1 phase cell cycle arrest by increasing P27 protein levels (Rao, 
1998).  P27 also causes cells to differentiate.  In 2000, Quaroni showed that P27 
expression in human intestinal epithelial cells led to the expression of differentiation 
markers at both the mRNA and protein levels (Quaroni, 2000).  Troncone showed that 
poorly differentiated carcinomas had much less P27 immunostatining than carcinomas 
that were more differentiated (Troncone, 2004).  Indeed, Millard showed high levels of 
P27 in HL60 cells treated with a known differentiation reagent called 12-O-
tetradecanoylphorbol-13-acetate or TPA (Millard, 1997).  P27 has also been implicated in 
apoptosis and has been shown to be a regulator of drug resistance in solid tumors (Lloyd, 
1999).   
Because P27 is known to cause cell cycle arrest as well as promote cellular 
differentiation, there is a great interest in the scientific community to discover how P27 is 
regulated.  If the mechanism of P27 induction is fully understood, one could foresee 
future chemotherapies that might be used to treat cancer by activating or increasing P27 
expression.
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1.6  The Regulation of P27 
The regulation of P27 has been under intensive debate.  It has been shown by Carrano 
and Tsvetkov that P27 is phosphorylated at Thr 187 by CDK2/Cyclin E and this 
phosphorylation is then recognized by Skp 2 which targets it for proteosome degradation 
(Carano, 1999; Tsvetkov, 1999; Chen 2005).  It was also found that lovastatin increased 
P27 protein levels without a significant increase in mRNA (Hengst, 1996).  Thus, it was 
suggested that P27 expression may be regulated only by translation and/or protein 
stability.  Indeed, Millard found a U rich region in the 5’UTR that seemed to be important 
for the translation of P27 (Millard, 2000).  It was later suggested that the P27 5’UTR has 
an internal ribosome entry site (IRES) which allows for cap independent translation of its 
mRNA (Miskimins, 2001).  This IRES activity appears to be increased by inducing 
differentiation of HL60 cells with TPA (Cho, 2005).  However, the existence of an IRES 
in the 5’UTR of P27’s mRNA has been challenged due to the inherited technical 
problems of the dicistronic vectors used in these studies.  Using Northern blot analysis, 
Kulman et al. observed that the full length 5’-UTR of P27 (575 bases) potentially 
contains a cryptic promoter (Kullman, 2002).  Later, Liu et al. (Liu, 2005) demonstrated 
that there is a cryptic promoter in the 5’-UTR of P27. This cryptic promoter may be 
present in a region between 549 and 511 nucleotides (Gizard, 2005).  In addition, another 
promoter was identified in a region between 774 and 462 of the 5’UTR (Chen, 2005).   
1.7  Aim and Significance of My Thesis Project 
As mentioned above, it has been found that P27 expression is stimulated by lovastatin 
treatment (Hengst, 1996) and that this drug is known for its ability to cause cell cycle 
arrest in the G1 phase of the cell cycle by increasing P27 protein levels (Rao, 1998).  
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Lovastatin is a drug that helps to lower cholesterol levels in the body.  It is in the class of 
medications called HMG-CoA reductase inhibitors.  HMG-CoA reductase is required to 
convert 3-hydroxy-3methylglutaryl-coenzyme A to mevalonic acid.  Biosynthesis of 
cholesterol requires mevalonic acid as a precursor.  As a result, lovastatin is very 
effective in lowering low density lipoprotein levels (Lampercht, 1999).  In addition to its 
role in forming cholesterol, mevalonic acid has been suggested to be involved in forming 
some non-sterol products that are important in cell cycle progression.   
The hypothesis being tested in this thesis is that cryptic promoters in the 5’-UTR of 
P27 are responsible for lovastatin stimulation of P27 expression. To this end, the full 
length 5’UTR sequence of P27 was inserted upstream of a luciferase reporter gene, 
transfected into HeLa cells, and subjected to treatment by 81 µM of lovastatin for 24 
hours.  This treatment resulted in a two fold increase in the luciferase reporter protein as 
well as P27 mRNA.  The response elements were mapped to the regions of 575-559 and 
543-527 bases upstream of the start codon.  These promoters are located in the same 
regions as those identified by Gizzard and Chen (Gizzard, 2005; Chen, 2005). In 
addition, the same two regions that are sensitive to lovastatin treatment were also 
responsive to serum starvation.  Thus, it is possible that the 5’UTR of P27 has two cryptic 
promoters that may be responsive to cellular stress. 
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CHAPTER 2.  MATERIALS AND METHODS 
2.1  Reagents 
Lovastatin (Mevolin) was purchased from Sigma Aldrich.  Large scale preparation 
and plasmid purification kits were purchased from Qiagen.  DMEM 1x for cell culture 
was a product of Cellgro while the Trypsin-Versene Mixture was purchased from 
BioWhitaker.  Lipofectamine and Plus reagent were purchased from Invitrogen and 
iscript cDNA synthesis kit came from Biorad.  Dnase and RNAsin were obtained from 
Promega. 
2.2  Bacterial Strain and Media 
E. coli DH5 alpha, the routinely used strain for molecular cloning and plasmid 
amplification, was grown in Luria’s Broth, LB (for 1 liter:  10g Bacto tryptone, 5 g BAct 
yeast extract, 10 g sodium chloride and pH adjusted to 7.0 with 10 M NaOH).  LB agar 
plates were made by adding 15 g Difco agar to 1 liter of LB.  Ampicillin (100 µg/mL) 
was included in the LB plates for selection of ampicillin resistant transformants.  E. coli 
BMH 71-18 mut S was used for molecular cloning in mutant plasmids.  This E. coli was 
also grown in Luria’s Broth that was made from the procedure described above.  50 
ug/mL of tetracycline was included in the LB plates for selection of tetracycline resistant 
transformants.   
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2.3  Bacterial Cell Transformation - Large Scale Preparation 
Cells were cultured in a LB agar plate supplemented with ampicillin and grown 
overnight in a 37° C incubator.  One colony was chosen and then grown overnight in 250 
mL of LB that contained .1% ampicillin.  The ampicillin resistant clones were then 
harvested and the desired plasmid was isolated and purified using the Qiagen Midi Kit. 
2.4  Buffers and Solutions 
TSS solution was made for the creation of insertional mutations.  TSS solution was 
made with 80% LB, 10% PEG, 5% DMSO and 50 mM of Magnesium Chloride.  This 
solution was mixed together and then autoclaved to prevent bacterial contamination. 
2.5  Bacterial Cell Transformation - Linker Scanning Mutagenesis 
For BMH 71-18 mut S E. coli used for linker scanning mutagenesis, previously 
prepared BMH E. coli was streaked on an LB dish containing 1.5% agar and 50 µg/mL of 
tetracycline and incubated overnight in a 37° C humidified incubator.  A single colony 
was then taken and placed in a tube with 5 mL of LB containing 50 µg/mL of tetracycline 
and shaken at 37° C overnight.  After overnight incubation, 250 µL of this culture was 
then added to 25 mL of LB with no tetracycline and cultured at 37° C for about 2.5 hours 
or until the OD600 is about 0.5 on the spectrometer.  The flask is then put on ice for 20 
minutes.  The E. coli is subsequently spun down at 4° C for five minutes, the LB is 
removed, and 2.5 mL of TSS solution is added.  After resuspending the E. coli in TSS 
solution, the mixture is placed on ice for use in linker scanning mutagenesis 
transformation.  
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2.6  Primers for cDNA 16 Nucleotide Mutations 
Mutation primers were made for the appropriate restriction enzymes (Bam H1 and Sal 
1) as well as to create 16 nucleotide mutations from 575 to 496 of the P27 5’UTR.  The 
mutated sections are underlined. 
Restriction enzyme Mutations: 
Bam H1:  TGT GGT AAA ATC GAT AA GCTACG G TCG ACC GAT GCC CTT G 
Sal 1:  GT AAA ATC GAT AA G CTA CG G TA AACC GAT GCC CTT GAG AGC CT 
5’Untranslated Region Mutations: 
M1:  CTC TTA CGC GTG CTA GT ACTCTAGACTCTAGAC CTC GCC AGC CTC GGC GG 
M2:  TCC ACC TTA AGG CCG CG ACTCTAGACTCTAGAC GGG CGG CTC CCG CCG CC 
M3:  GCT CGC CAG CCT CGG CG ACTCTAGACTCTAGAC CGC AAC CAA TGG ATC TC 
M4:  GGG GCG GCT CCC GCC GC ACTCTAGACTCTAGAC CCT CCT CTG TTT AAA TA 
M5:  CCG CAA CCA ATG GAT CT ACTCTAGACTCTAGAC AGA CTC GCC GTC TCA AT 
M1/M3  CTC TTA GCG GTC CTA GT ACTCTAGACTCTAGATCC ACC TTA AGG CCG CG ACTAGACTCTAGAC CGC AAC CAA   
               TGG ATC TC 
 
2.7  Creation of cDNA Mutations—Linker Scanning 
Primers, annealing buffer, and template were added to a microcentrifuge tube and 
boiled for ten minutes.  Samples were then cooled in ice + water and 10 x synthesis 
buffer, T4 DNA polymerase, and T4 DNA ligase were subsequently added.  After 
incubation at 37° C for two hours, the reaction was stopped by incubating at 70° C for 
seven minutes and cooled at room temperature for 30 minutes.  Annealing buffer and the 
appropriate digestion enzyme (Sal 1 or Bam H1) were then added and incubated at 37° C 
for an additional two hours.  After the appropriate mutant is added to 200 uL of TSS 
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solution, the plasmid is added to the E. coli mixture and cultured overnight in a 37 C 
shaker.  The bacterial cells are then purified using the Qiaspin Prep Miniprep Kit.  After 
the first transformation, plasmids are digested again with the appropriate digestion 
enzyme (Sal 1 or Bam H1).  30 or 100 uL of the plasmid are then plated on LB agar 
plates and incubated overnight.  The plasmids are purified with the Qiaspin Prep 
Miniprep Kit.    
2.8  Cell Culture and Transfection 
Cells were plated in 35 mm dishes and cultured as described above.  After three hours 
of transfection, the medium was changed to DMEM with serum and incubated for an 
additional 24 hours.   
2.9  Lovastain Treatment/Serum Starvation   
Twenty four hours after transfection, HeLa cells were exposed to 81 µM of lovastatin 
dissolved in Ethanol for an additional 24 hours.  Control cells were given appropriate 
amounts of Ethanol only.  Serum starvation cells were exposed to either “starvation 
conditions” (DMEM without serum) or control conditions (DMEM with 10% serum) for 
an additional 48 hours.   
2.10  RNA Analysis  
Harvesting Cells and Isolation of RNA:  HeLa cells were washed and RNA was 
isolated and purified using Qiagen’s RNeasy Mini Kit.   
Real-Time PCR Primers:  Primers were developed from Invitrogen and had the 
following forward and reverse sequences: 
Luciferous Forward:  5’ GCG AAG GTT GTG GAT CTG 3’ 
Luciferous Reverse:  5’ CAC ACA CAG TTC GCC TCT TTG 3’ 
B Galactosidase Forward:  5’ TGC TGC ACG CGG AAG AA 3’ 
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B Galactosidase Reverse:  5’ AGT CGT CGC CAC CAA TCC 3’ 
Endogenous P27 Forward:  5’ CTC TGA GGA CAC GCA TTT GGT 3’ 
Endogenous P27 Reverse:  5’ CGC ATT GCT CCG CTA ACC 3’ 
Endogenous GADPH Forward:  5’  AAG GAC TCA TGA CCA CAG TCC 3’ 
Endogenous GADPH Reverse:  CCA TCA CGC CAC AGT TTC 3’ 
 
Real-Time PCR Analysis:  Reverse Transcriptase is added and RNA is subsequently 
converted to DNA using PCR.  The samples are then given the appropriate primers, 
SYBR Green, and the resulting Ct value is measured with a thermocycler.  Relative 
concentrations of DNA present during the exponential phase of the reaction are 
determined by plotting fluorescence against cycle number on a logarithmic scale.  
Amounts of DNA or RNA are then determined by comparing this value to a previously 
prepared standard curve.  Samples are normalized with B-galactosidase.  
2.11  Cell Cycle Analysis:  Flow Cytometry 
HeLa cells were washed with PBS and fixed with Ethanol.  Fifty ug/mL of Propidium 
Iodide and 200 ug/mL of RNAse are added and cell cycle is measured using FACS 
analysis.   
 15 
2.12  Protein Analysis:  Western Blot 
Cells were rinsed with PBS and lysed with .1% SDS Page sample buffer. (3 mL 
TNN; 1 mM DDT; 2 mM of PMSF; .1% SDS).  Equal amounts of protein were separated 
on SDS-polyacrylamide gels.  The cells were then transferred to a PVDF membrane and 
were processed as previously described (Wei, 2002).  Detection was carried out using a 
horseradish peroxidise conjugated secondary antibody and a chemiluminscent substrate.  
2.13  Statistical Testing 
    Samples were analyzed with Microsoft Excel to determine the p value and t test. 
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CHAPTER 3.  RESULTS 
3.1  Lovastatin Causes G1 Phase Cell Cycle Arrest by Increasing the P27 Protein 
Level 
 
It has been shown previously that lovastatin causes G1 phase cell cycle arrest in HeLa 
cells by increasing the level of P27 protein (Hengst, 1996).  To confirm these results, 
HeLa cells were treated with 81 µM of lovastatin (L+) or vehicle ethanol control (L-) for 
24 hours.  The cell cycle was subsequently analyzed by flow cytometry and P27 protein 
levels were examined by Western blot.  Figure 4A shows that cells treated with 81 µM of 
lovastatin had 70% of their cells in the G1 phase of the cell cycle.  Twenty-five percent of 
the lovastatin-treated cells were in the S phase and 5% were in the G2 phase.  In contrast, 
vehicle control treated cells had less than 50% of their cells in the G1 phase, 40% in the S 
phase and 10% in the G2 phase.  Thus, lovastatin can arrest cells in the G1 phase of the 
cell cycle. 
As shown in Figure 4B, HeLa cells treated with lovastatin had more than three times 
the amount of P27 protein compared with those treated by the vehicle control.  Thus, it is 
likely that lovastatin increases P27 protein expression which in turn results in cell cycle 
arrest in the G1 phase.  These results confirmed previous findings that lovastatin 
increases the levels of P27 protein (Hengst, 1996). 
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Lanes 1 2 3 4 
Lovostatin yes no yes no 
 
 
 
 
 
Figure 4A 
Figure 4B 
Figure 4:  Cell cycle analysis and western blot of HeLa cells exposed to 81 
uM of Lovastatin.  1.2 x 106 HeLa cells were plated on 6 well plates, 
incubated for 48 hours, and then subject to 81 µM of lovastatin (L+) or 
ethanol (L-) for an additional 24 hours.  HeLa cells were then analyzed by 
flow cytometry for cell cycle distribution (A) and by western blot for P27 
expression (B).  Statistically significant results in the G1 phase of the cell 
cycle (p<.05) are shown with the * symbol.  GADPH was used as a loading 
control. 
 
          P27 
           GADPH levels 
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3.2  Lovastatin and its Effect on P27 5’UTR Deletion Mutations 
Previously, it has been found that P27 was regulated by translation via an IRES site in 
its 5’UTR (Miskimins, 2001).  However, this finding has been disputed by other studies 
which showed that the presumed IRES in the 5’-UTR may be a cryptic promoter instead 
(Kullman, 2002; Liu, 2005; Gizard, 2005).  In order to understand if P27 is regulated by a 
cryptic promoter rather than an IRES and if this promoter is responsible for lovastatin 
stimulation, various monocistronic DNA constructs were created (Figure 5A).  These  
constructs were then transfected into HeLa cells followed by treatment with or without 
lovastatin and the promoter activity was measured by determining the reporter level. As 
shown in Figure 5B, the full length P27 5’UTR (575 bases) showed a 1.4 fold increase in 
luciferase activity.  However, the deletion constructs with 540, 496, and 150 bases of the 
5’-UTR had very little increase in luciferase expression following the exposure to 
lovastatin.  In addition, the total level of luciferase activity decreases substantially when a 
5’-UTR with 540 nucleotides or less is used.  These results suggest that a lovastatin 
response element may be located between 540 and 575 nucleotides.  
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Fold:            .528        1.07            1.00               1.23               1.41 
 
Figure 5A 
 Figure 5B 
Figure 5:  Luciferase Analysis of P27 deletion mutations.  5A:  Deletion mutation constructs 
inserted upstream of the luciferase gene.  F Luc. Stands for Firefly Luciferase.  5B:  Relative 
luciferase activity for HeLa cells transfected with deletion mutations and exposed to 81 µM 
of lovastatin for 24 hours. Cells not exposed to lovastatin, L-, were given equal amounts of 
ethanol.  Cells were then harvested and analyzed for luciferase analysis.  All samples are 
measured in RLU (Relative Light Units).  Samples were normalized with B-galactosidase.  
All samples are expressed relative to the PGL3 vector control.  (N=number of experiments.  
* = p<.05; ** = p<.01; *** = p <.001) 
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3.3  Mapping the Lovastatin Response Element in the Region From 575-540 of P27’s 
5’UTR by Linker Scanning Mutagenesis 
 
To define the putative lovastatin response element between 540 and 575 nucleotides 
of the P27 5’UTR, linker scanning mutagenesis was used.  Figure 6A shows the resulting 
constructs.  These constructs were transfected into HeLa cells to determine their response 
to lovastatin.  As shown in Figure 6B, the total luciferase activity was decreased by 
mutations M1 and M3 in the regions of 575-559 and 543-527.  This indicates that 
promoter elements may exist in the regions of M1 or M3.  These promoter elements also 
appear to be sensitive to lovastatin.  At 81 µM of lovastatin, both M1 and M3 showed a 
decrease in lovastatin-stimulated luciferase expression compared with the wild type P27 
5’-UTR.  Taken together, it is possible that there may be two lovastatin response 
elements; one in the M1 region (575-559) and the other in the M3 region (543-527).  In 
addition, it is possible that these two response elements may cooperatively work together 
and mutating any one of them may not be enough to completely eliminate the lovastatin 
response. 
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Fold:      1.44          1.22          1.81          1.51            1.97           1.71 
KEY: 
M1 = 575-559 
M2 = 559-543 
M3 = 543-527 
M4 = 527-511 
M5 = 511-495 
Figure 6B  
Figure 6: Luciferase analysis of 16 nucleotide insertional mutations transfected 
into HeLa cells and exposed to Lovastatin.  6A: Mutations made by linker 
scanning mutagenesis. 6B:  Luciferous activity of Mutants 1-5 after transfecting 
them into HeLa cells and incubating them with 81 µM of lovasatin for 24 hours.  
(N=number of experiments.  RLU = Reflective Light Units.  * = p<.05; ** = 
p<.01; *** = p <.001) 
 
 
 
Figure 6A 
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3.4  Effect of the M1/M3 Double Mutant (575-559, 543-527) on Lovastatin Response 
To test if M1 and M3 do indeed work cooperatively, a new plasmid was created 
(M1/M3) that has mutations in both the M1 and M3 of P27’s 5’UTR.  (575-559; 543-
527) (Figure 7A).  This newly created plasmid was then transfected into HeLa cells and 
subject to 81 µM of lovastatin as described above (See 3.4).  Figure 7B indicates that the 
total luciferase activity with the M1/M3 construct is significantly lower than either the 
M1 or M3 constructs and all are much lower compared with the wild type 5’UTR of P27.  
In addition, HeLa cells transfected with M1/M3 show a statistically insignificant 1.18 
fold increase with cells exposed to 81 µM of lovastatin.  This provides further evidence 
that the lovastatin response elements are likely present in both the M1 and M3 regions.   
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Fold:                1.34              1.17               1.42               1.18 
 
Key: 
M1 = 575-559 
M3 = 543 – 527 
M1/M3 = 575-559;                       
543-527 
Figure 7A  
Figure 7B 
Figure 7: Luciferase analysis of newly transfected M1/M3 mutant (575-
559; 543-527) transfected into HeLa cells and exposed to Lovastatin. 7A:  
Creation of the M1/M3 mutant using the same linker scanning procedure 
described previously.  7B:  P27 5’UTR; M1, M3, and M1/M3 were 
transfected into HeLa cells and treated with 81 µM lovastatin for 24 hours.  
Luciferase activities were then measured on a luminometer.  (N=number of 
experiments run.  * = p<.05;  ** = p<.01; *** = p<.001) 
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3.5  RNA Analysis of P27 5’UTR Mutants Exposed to 81 µM of Lovastatin 
Since there seems to be lovastatin response elements in both the M1 (575-559) and 
M3 (543-527) regions of P27’s 5’UTR, the RNA level of luciferase was then measured to 
confirm the existence of these elements in our newly created plasmids.  HeLa cells were 
transfected with either P27 (575), M2 (559-543), M1/M3 (575-559; 543-527), or SP27 
(150) (a very minimal P27 promoter) and exposed to 81 µM of lovastatin for 24 hours.  
RNA levels were then measured by real-time PCR (RT-PCR).  Figure 8 indicates that 
both the wild type P27 and the mutant M2 control had an increase in RNA levels 
following lovastatin treatment. (Figure 8)  As expected, the double mutant M1/M3 shows 
no change in RNA levels when subject to these conditions (Figure 8).  Thus, there may be 
two lovastatin sensitive promoters (M1: 575-559 and M3:  543-527) that function 
cooperatively to increase the transcription of P27. 
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Fold:               1.09                      1.58                        2.28                         1.04 
 
Figure 8 
Figure 8:  RNA analysis of P27 mutated plasmids exposed to 81 uM of lovastatin.  SP27 
deletion mutation (150), P27 (575), Mutant 2 – (559-543), and M1/M3 [(575-559); (543-
527)] were transfected into HeLa cells, incubated for 24 hours, and then subject to 81 µM 
of lovastatin in procedures described previously.  RNA was then harvested and analyzed. 
by real-time PCR.  (N = number of experiments.  * = p < .05) 
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3.6  Endogenous RNA Analysis of P27 Exposed to 81 µM of Lovastatin 
Previous results indicate that two lovastatin sensitive elements are located in the 
5’UTR of P27.  To further determine if endogenous P27 RNA is also increased following 
lovastatin treatment, RT-PCR was performed with endogenous P27.  As shown in Figure 
9, a 1.6 fold increase in endogenous P27 RNA was observed with HeLa cells exposed to 
81 µM of lovastatin for 24 hours.  These results are comparable to the 1.5 fold increase 
observed with the P27 5’UTR luciferase construct in HeLa cells treated with the same 
conditions.  Thus, it is possible that lovastatin increases the endogenous P27 expression 
via two response elements in its 5’UTR:  M1 (575-559).and.M3 (543-527).  
 
  
   
3.7  Cell Cycle Analysis of HeLa Cells Exposed to Starvation Conditions 
Figure 9:  Endogenous RNA analysis of P27 plasmids exposed to 81 µM of lovastatin.  Cells 
were plated, incubated for 48 hours, and exposed to 81 µM of lovastatin for an additional 24 
hours.  HeLa cells were then harvested and RNA was subsequently isolated.  Endogenous 
P27 was measured using Real Time PCR.  Endogenous P27 RNA samples were normalized 
with the housekeeping gene GADPH.  (N = number of experiments.  * = p < .05) 
 
Figure 9 
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3.7  Cell Cycle Analysis of HeLa Cells Exposed to Starvation Conditions  
In addition to lovastatin, cell synchronization in the G1 phase of the cell cycle can be 
achieved by serum starvation.  Chou published a paper in 1999 showing that a Chinese 
hamster ovary cell line (CHO K1) could be effectively arrested in the G1 phase of the cell 
cycle through serum starvation (Chou, 1999).  In a more recent study on dermal 
fibroblasts, a statistically significant increase of cells in the G1 phase was observed upon 
exposure to serum starvation (Khammanit, 2008).  Moreover, Shin observed decreases in 
CDK2 and CDK4 activity in ovarian cancer cells that were exposed to serum starvation 
(Shin, 2008).   
To see if HeLa cells could also be synchronized in the G1 phase, cells were plated 
onto six well plates and incubated for 48 hours.  Cells were then subjected to starvation 
conditions for 48, 96, or 144 hours respectively.  Cells that were incubated for 48 hours 
under normal conditions showed 40% in G1, 55% in S, and 5% in the G2 phase of the 
cell cycle.  In contrast, cells incubated without serum showed 53% in G1, 30% in S, and 
12% in the G2 phase of the cell cycle.  As expected, cells incubated without serum at 96 
and 144 hours showed similar results to those incubated for only 48 hours (Figure 10).  
This shows either serum starvation or lovastatin incubation can arrest cells in the G1 
phase of the cell cycle.  Indeed, starved HeLa cells exposed to 81 µM of lovastatin had 
83% of their cells arrested in the G1 phase.   
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Figure 10 
Figure 10:  Cell cycle analysis of HeLa cells exposed to starvation conditions.  1.2 x 105 
cells (S+, S+/L+, S- 48 hours, S- 96 hours, S- 144 hours) were plated on a 6 well plate, 
incubated for 48 hours, and then subject to starvation conditions for 48, 96, or 144 hours.  
Cells were then analyzed by FACS analysis (* = p < .05). 
S+ .1% S+ S- S- S- S+/L+ S-/L+ 
48 Hrs. 48 Hrs. 48 Hrs. 96 Hrs. 144 Hrs. 48 Hrs. 48 Hrs. 
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3.8  Luciferase Analysis of P27 Transfected HeLa Cells Exposed to Starvation 
Conditions 
 
Since HeLa cells could be synchronized in the G1 phase of the cell cycle, P27 5’UTR 
mutant plasmids were transfected into HeLa cells to determine how luciferase activity 
was affected.  After cells were transfected with P27 plasmids, they were incubated for 24 
hours and then subject to either starvation (DMEM without serum) or control (DMEM 
with serum) conditions for an additional 48 hours followed by analysis of luciferase 
activity.  As shown in Figure 11, the full length P27 5’UTR had a 1.4 fold increase in 
luciferase activity.  (Figure 11)  This is identical to the results seen in HeLa cells exposed 
to 81 µM of lovastatin (Figures 5 and 7).  In contrast, the 496 deletion construct (NP27) 
showed no increase in luciferase activity in response to starvation conditions which is 
also consistent with our previous results.  Furthermore, the plasmids M1 and M3 showed 
a statistically insignificant increase in luciferase activity when exposed to starvation 
conditions for 48 hours.  When the double mutant M1/M3 was analyzed, there was no 
increase (Fold = .81) in luciferase activity in response to serum starvation (Figure 11B).  
These results suggest that the two lovastatin response elements, M1:  575-559 and M3:  
559-527, may also respond to serum starvation.   
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Fold:        1.39      1.06        1.67     1.35      1.88         1.87     1.02 
 
Fold:              1.39               1.07                1.35                .81                                   
 
KEY: 
M1 = 575-559 
M2 = 559-543 
M3 = 543-527 
M4 = 527-511 
M5 = 511-495 
 
Key: 
M1 = 575-559 
M3 = 543 – 527 
M1/M3 = 575-559; 543-527 
 
Figure 11A 
Figure 11B 
Figure 11:  Luciferase Analysis of 16 nucleotide deletion mutations 
transfected into HeLa cells and exposed to starvation conditions.  11A 
& B:  P27 mutants were transfected into HeLa cells, incubated for 24 
hours and subject to serum starvation conditions for 48 hours.  Cells 
were then harvested, lysed, and activity was analyzed on a luminometer.  
(N = number of experiments.  * = p<.05;  ** = p<.01;  *** = p<.001) 
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3.9  RNA Results of HeLa Cells Exposed to Starvation Conditions 
We next determined RNA levels to confirm that serum starvation causes an increase 
in P27 transcription.  HeLa cells were exposed to starvation conditions for 48 hours with 
the resulting total RNA being measured.  Figure 12A showed a 1.5 fold increase in P27 
RNA which is comparable to the 1.5 fold increase in RNA when HeLa cells were 
exposed to lovastatin.  When cells were exposed to starvation conditions and M2 RNA 
was measured, there was a 2.5 fold increase in RNA compared to the serum control.  In 
contrast, there was no RNA increase in SP27 (150) or M1/M3 (575-559, 543-527)  
(Figure 12A).  To see if this only affects manufactured plasmids, endogenous P27 levels 
were measured from HeLa cells exposed to starvation conditions for 48 hours.  Figure 
12B indicates a statistically significant 1.3 fold increase in P27 levels.  This statistically 
significant increase provides further evidence that there are two starvation senstitive 
promoters:  M1 (575-559) and M3 (543-527).  Since these results are similar to those 
when HeLa cells were exposed to lovastatin, it suggests that cellular stress increases P27 
levels through the process of transcription.  This hypothesis, however, requires a Western 
Blot analysis to confirm if serum starvation does infact cause an increase in endogenous 
P27 protein.   
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Figure 12A 
Fold:                 .89                       1.56                     2.64                  .89 
 
Figure 12B 
Figure 12:  RNA analysis of HeLa cells exposed to starvation conditions.  12A:  SP27 deletion 
mutation (150), P27 (575), Mutant 2 (559-543), and M1/M3 (575-559; 543-527) were 
transfected into HeLa cells, incubated for 24 hours, and subject to starvation conditions for 48 
hours.  RNA was then isolated and analyzed through Real Time PCR.  12B:  HeLa cells were 
plated, incubated for 48 hours, and subject to starvation conditions for 48 hours.  HeLa cells 
were then harvested and RNA was subsequently isolated.  Endogenous P27 RNA levels were 
then measured using Real Time PCR. Endogenous P27 samples were normalized with the 
housekeeping gene GADPH. (N=number of experiments.  * = p<.05; ** = p <.01; *** = p<.001) 
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CHAPTER 4.  DISCUSSION 
Our results indicate that P27 contains two cooperatively functioning lovastatin 
response elements in both the M1 (575-559) and M3 (559-543) regions of the 5’UTR.  
This was shown through both luciferase reporter analysis and real-time PCR.  In addition 
to being responsive to lovastatin, these two regions are also sensitive to serum starvation.  
This suggests that P27 expression may be regulated by other aspects of cellular stress in 
addition to lovastatin at the transcriptional level. 
Lovastatin has been shown to arrest HeLa cells in the G1 phase of the cell cycle.  
(Hengst, 1996).  Indeed, Figure 4 indicates that over 70% of the cells were arrested in the 
G1 phase after being exposed to 81 µM of lovastatin for 24 hours.  Furthermore, there 
was also a two fold increase in P27 protein expression in cells exposed to lovastatin.  
HeLa cells that were subject to starvation for 96 hours had 60% of the cells arrested in 
the G1 phase (Figure 10).  This suggests that both lovastatin and serum starvation arrest 
cells in the G1 phase of the cell cycle by increasing the expression of P27.  Although 
there is no previous study indicating the effects of serum starvation on P27 levels, 
Khammanit showed a statistically significant increase of cells in the G1 phase upon 
exposure to starvation conditions for 48 hours (Khammanit, 2008).   
Furthermore, Shin observed decreases in CDK2 and CDK4 activity in ovarian cancer 
cells that were exposed to serum starvation (Shin, 2008).  P27 is a known inhibitor of 
CDK2.  This suggests that P27 may cause cell cycle arrest in starved HeLa cells in 
addition to cells exposed to 81 µM of lovastatin.  To confirm this, however, a Western 
blot needs to be performed to determine if P27 protein levels increase under starvation 
conditions.    
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When HeLa cells transfected with the P27 5’UTR-Luciferase construct were exposed 
to 81 µM of Lovasatin for 24 hours, there was a statistically significant 1.4 fold increase 
in luciferase activity (Figure 5).  In turn, there was also a 1.4 fold increase in luciferase 
activity in cells exposed to starvation conditions (Figure 11).  In contrast, there was no 
change in luciferase activity in 540, 496, or 150 5’UTR deletion mutations.  Since these 
were monocistronic constructs, this data contradicts the concept that Minikimis proposed 
where P27 regulation is controlled by an IRES site (Minikims, 2001).  If P27 5’UTR did 
indeed contain an IRES that regulated translation, there should be no luciferase activity 
present when the cell lysate was analyzed on a luminometer.  Instead, however, there was 
an increase in luciferease activity when transfected HeLa cells were subject to 81 µM of 
lovastatin or starvation conditions.  This suggests that lovastatin or serum starvation 
increases the P27 protein through transcription by activating a promoter in the 5’UTR.   
When deletion mutations were made from nucleotides 496-575, all five mutations had 
some response to lovastatin.  Two mutations, however, had a lower total luciferase 
activity:  M1 (575-559) and M3 (543-527).  Since these two mutations had significantly 
lower activity than P27, M2, M4, or M5, a new M1/M3 mutant was made with deletions 
in both regions of the 5’UTR (575-559; 543-527).  This newly created mutant showed no 
lovastatin-stimulated increase in luciferase activity.  Since there was an increase in 
luciferase activity with both M1 and M3 but not M1/M3, there seems to be two 
cooperatively functioning luciferase response elements: M1 (575-559) and M3 (543-527).  
When Real Time RT-PCR was run, there was no increase in RNA levels with either 
serum starvation (Figure 12A) or 81 µM of lovastatin (Figure 8).  These results are 
further validated by Gizard which showed a region between 549 and 511 nucleotides that 
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caused an increase of P27 mRNA with the addition of progesterone (Gizard, 2005).  
Taken together, these results suggest that cellular stress causes G1 phase cell cycle arrest 
by increasing the transcription of P27 via activating both the M1 and M3 response 
elements. 
In 1996, Hengst indicated that endogenous P27 protein increased upon lovastatin 
incubation.  This paper also showed no change in P27 RNA when measured on a 
Northern blot.  A Northern blot, however, is not as sensitive as real-time PCR.  Because 
of this and our previous results, HeLa cells were exposed to 81 µM of lovastatin or 
starvation conditions after which endogenous P27 RNA was measured via real-time PCR.  
With 81 µM of lovastatin, there was a 1.6 fold increase in endogenous P27 mRNA.  
There was also a statistically significant 1.3 fold increase in P27 mRNA when HeLa cells 
were exposed to starvation conditions.  These results contradict Hengst conclusion that 
the increase in P27 protein is entirely due to translational regulation.  Futhermore, this 
data confirms that P27 RNA does increase via transcription when HeLa cells are subject 
to cellular stress.  
Uncontrolled cellular proliferation is one of the major causes of tumorigenesis.  If 
cells continue to proliferate indefinitely, repair is unable to occur which allows for 
transitions, transversions, double stranded breaks and other errors to permanently 
incorporate themselves into DNA.  In addition, uncontrolled cellular proliferation causes 
already formed initiated cells to develop into full blown tumors.  This is why it is 
important to understand the regulation of cyclin dependent kinases.  These kinases, which 
promote the growth of the cell cycle, are regulated by various proteins such as P27, P21, 
and P57.   
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P27 causes cells to be arrested in the G1 phase of the cell cycle by inhibiting Cyclin 
E/CDK2.  Low amounts of P27 have lead to a poor prognosis in many types of human 
cancers including breast, prostate, and ovary.  This is partly because low P27 amounts 
prevent cells from being arrested in the G1 phase of the cell cycle.  It is also because P27 
causes cellular differentiation which prevents the formation of metastatic cancers.   
Trocone helped to verify this by publishing a paper showing higher amounts of P27 
protein in benign lesions in contrast to those in malignant breast lesions (Troncone, 
2004).   
Although our P27 promoter only gives a 1.5 fold increase in response to lovastatin or 
serum starvation, it does suggest that P27 is regulated at the level of transcription.  This 
regulation has also been shown by Kulman who found two bands on a northern blot when 
the full length 5’UTR (575 nucleotides-located on a bicistronic construct) was analyzed 
(Kulman, 2002).  P27’s 5’UTR has also been shown to be regulated by transcription in 
other cell lines such as T467D and prostate cancer cells.  In all of these experiments, the 
promoter has been shown to be in the region of 575 to 540 nucleotides of the P27 5’UTR 
(Gizard 2005; Roy 2007).  Since results are similar when HeLa cells are exposed to either 
lovastain or starvation conditions, it is possible that P27 is regulated by transcription via 
cellular stress.  Indeed, Gizzard showed that Silibinin increases P27 RNA levels and Roy 
indicated that progesterone also increased P27 through transcription (Gizard 2005; Roy 
2007).  Transcriptional regulation does not explain the total increase in P27 protein, since 
there was only a 1.6 fold increase in endogenous P27 RNA while there was over a three- 
fold increase in P27 protein when 81 µM of lovastatin was incubated for 24 hours (Figure 
4 and 9).  Furthermore, other studies from Carrano and Hengst suggest that P27 is 
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regulated during translation and at the level of proteosomal degredation (Carano, 1999; 
Hengst, 1996).  This suggests that P27 is regulated at multiple levels in response to 
cellular stress.  Hopefully, scientists will be able to manipulate one or more of these 
aspects of regulation in the future.  This could lead to treatments that increase P27 to 
prevent the formation and progression of cancer.   
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